Diabetic Foot Ulcer Clinical Trial
— DFUsOfficial title:
A Prospective, Multicenter, Randomized, Controlled Clinical Study Of NuShield® and Standard of Care (SOC) Compared to SOC Alone For The Management Of Diabetic Foot Ulcers
Verified date | May 2021 |
Source | Organogenesis |
Contact | Galen Hale |
Phone | (205) 541-9682 |
GHale[@]organo.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This prospective, multi-center, randomized, controlled clinical study compares NuShield® plus SOC to SOC alone in subjects with chronic DFUs. NuShield® will be used along with standard of care on diabetic foot ulcers of greater than 6 weeks which have not adequately responded to conventional ulcer therapy.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | December 30, 2021 |
Est. primary completion date | November 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. At least 18 years old and maximum of 85 years old. 2. Subjects with a diabetic foot ulcer that is either superficial, e.g. not involving tendon, capsule, or bone; or wounds that penetrate into tendon, capsule, bone and/or joint. 3. Subjects, with the presence of Diabetes, must have a Glycosylated hemoglobin (HbA1c) = 12% within 4 weeks prior to randomization 4. Index ulcer (i.e. current episode of ulceration) has been present for greater than 4 weeks prior to the initial screening visit with no upper limit in duration of non-healing. 5. Subject has adequate circulation to the foot as documented by either: Skin perfusion pressure (SPP) measurement of = 45 mmHg, Toe-brachial index (TBI) = 0.6/ Toe pressure greater than 40, Ankle-brachial index (ABI) between 0.60 and = 1.3 6. Index ulcer is a minimum of 0.5 cm2 and a maximum of 25cm2 at randomization, prior to first study treatment. 7. The index ulcer has been offloaded for 14 days prior to randomization. 8. Index ulcer has not reduced in area > 20% from Day -14 to Day 0, prior to randomization. 9. Subject understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen. 10. Subject, or their Legally Authorized Representative (LAR), has read, understood, and signed the IRB/IEC approved Informed Consent Form before screening procedures are undertaken. Exclusion Criteria: 1. Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes. 2. Treatment with HBO wound dressings that include growth factors, bioengineered tissues, or skin substitutes within 30 days of randomization. 3. History of bone cancer or metastatic disease of the affected limb or chemotherapy within the 12 months prior to randomization. 4. Subjects with a history of more than two weeks treatment with immunosuppressants (including prednisone 10 mg daily or an equivalent does of other oral steroids cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within one month prior to first Screening Visit, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study. 5. Subject is on any investigational drug(s) or therapeutic device(s) within 30 days preceding the first Screening Visit. 6. History of radiation at the ulcer site. 7. Index ulcer has been previously treated or will need to be treated with any prohibited therapies within 30 days prior to randomization. 8. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment. 9. Active infection at the index ulcer at the time of Randomization. 10. Acute osteomyelitis or bone infection of the affected foot, where subject has received less than 4 weeks of systemic antibiotics at the time of Screening and less than 6 weeks prior to Randomization (systemic antibiotic regimen must be completed at the time of Randomization). 11. Subject's with suspected infection who have received less than 2 weeks of systemic antibiotics, or have not had surgical resection of clinically diagnosed osteomyelitis 12. Subjects with suspected osteomyelitis who have not had an X-ray, CT scan or MRI within 14 days prior to Randomization. 13. Subject is unwilling or unable to comply with the study requirement for offloading the index wound 14. Subject is pregnant or breast feeding. |
Country | Name | City | State |
---|---|---|---|
United States | Family Foot & Ankle Specialists | Bridgeport | Connecticut |
United States | ILD Research Center | Carlsbad | California |
United States | Limb Preservation Platform | Fresno | California |
United States | University of Southern California | Los Angeles | California |
United States | Futuro Clinical Trials | McAllen | Texas |
United States | Doctors Research Network | Miami | Florida |
United States | NYU Winthrop Hospital | New York | New York |
United States | Stanford University | Redwood City | California |
United States | Extremity Healthcare | Roswell | Georgia |
Lead Sponsor | Collaborator |
---|---|
Organogenesis |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Length of time that a wound achieves complete wound closure (CWC) | Duration (number of days) to achieve CWC from baseline to week 12 assessed between both groups | 12 weeks | |
Secondary | Greater than 40% wound closure at week 4 from baseline | Proportion of subjects achieving = 40% wound closure at Week 4 from baseline | 4 weeks | |
Secondary | Change in wound area | Mean percent change from baseline in wound area at Week 12 | 12 weeks | |
Secondary | Incidence of prescribed pain and/or neuropathic medications | Cumulative amount of pain and neuropathic medications taken between baseline and Week 12 assessed between both groups. | 12 weeks | |
Secondary | Reduction in subject reported pain at week 12 from baseline assessed between both groups via the Numeric Pain Rating Scale (NPRS) | Mean percent change at week 12 in subject reported pain, assessed via the NPRS pain scale where 0 = no pain and 10 = worst pain imaginable, on a scale of 0 to 10. | 12 weeks | |
Secondary | Utilization of healthcare resources assessment | Utilization of healthcare resources through Week 12 | 12 weeks | |
Secondary | Improvement in subject reported quality of life at week 12 from baseline assessed via the Wound-QoL (Questionnaire on quality of life with chronic wounds). | Mean percent change at week 12 from baseline in subject reported quality of life scores between both groups. The 17 item Wound-QoL tool measures the disease-specific, health-related quality of life of patients with chronic wounds. A global score is computed by averaging all 17 items where subjects answer each question on a scale of 0 to 4, where 0=not at all and 4=very much. | 12 weeks | |
Secondary | Time to complete wound closure (CWC) by or on 24 weeks | Length of time wounds achieve CWC at week 24 from baseline | 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04497805 -
Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers
|
Phase 2 | |
Withdrawn |
NCT03675269 -
Adjunctive Hyperbaric Oxygen Therapy (HBOT) for Lower Extermity Diabetic Ulcer:
|
N/A | |
Completed |
NCT04624516 -
Effect of Self-foot Exercise on the Incidence of Plantar Foot Diabetic Ulcer Recurrence
|
N/A | |
Not yet recruiting |
NCT06439667 -
VIRTUALLY SUPERVISED TELE-EXERCISE PLATFORM FOR ACCELERATING PLANTAR WOUND HEALING
|
||
Recruiting |
NCT05608187 -
Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers
|
Phase 2 | |
Not yet recruiting |
NCT06278935 -
Lifestyle Tailored Offloading for Diabetic Foot Ulcers
|
N/A | |
Not yet recruiting |
NCT06437028 -
Evaluating the Efficacy of Perinatal Membrane Allografts for the Treatment of Diabetic Foot Ulcers.
|
N/A | |
Withdrawn |
NCT05024656 -
AmnioExcel® Plus vs SOC in the Management of Diabetic Foot Ulcers
|
N/A | |
Terminated |
NCT02202668 -
Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01951768 -
Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection
|
Phase 4 | |
Terminated |
NCT01966380 -
Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia
|
Phase 2 | |
Completed |
NCT01657474 -
Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers
|
N/A | |
Active, not recruiting |
NCT00389636 -
TheraGauze™ Alone and Regranex®Gel 0.01% Plus TheraGauze™ in the Treatment of Wagner Stage I Diabetic Foot Ulcers
|
N/A | |
Completed |
NCT01181440 -
Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers
|
Phase 3 | |
Enrolling by invitation |
NCT05888259 -
Plantar Pressure Distribution in Diabetic Foot Ulcer
|
N/A | |
Completed |
NCT04054804 -
Digital Foot Check by Using the D-Foot, a New Software
|
||
Not yet recruiting |
NCT05877378 -
Efficacy of PICO Single-use System in Chronic Ulcers
|
N/A | |
Recruiting |
NCT06037369 -
The Short Message-based Customized Standardized
|
N/A | |
Completed |
NCT03312595 -
Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
|
N/A | |
Recruiting |
NCT04564443 -
A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot
|
N/A |